Concurrent Investment Advisors LLC purchased a new stake in Xylem Inc. (NYSE:XYL - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 1,740 shares of the industrial products company's stock, valued at approximately $225,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in XYL. GAMMA Investing LLC lifted its stake in Xylem by 29.1% during the first quarter. GAMMA Investing LLC now owns 4,241 shares of the industrial products company's stock worth $507,000 after purchasing an additional 956 shares during the last quarter. Blue Trust Inc. lifted its stake in Xylem by 25.1% during the first quarter. Blue Trust Inc. now owns 539 shares of the industrial products company's stock worth $64,000 after purchasing an additional 108 shares during the last quarter. Center for Financial Planning Inc. lifted its stake in Xylem by 52.0% during the first quarter. Center for Financial Planning Inc. now owns 266 shares of the industrial products company's stock worth $32,000 after purchasing an additional 91 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund lifted its stake in Xylem by 7.6% during the first quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 7,027 shares of the industrial products company's stock worth $839,000 after purchasing an additional 494 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its stake in Xylem by 19.4% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 27,215 shares of the industrial products company's stock worth $3,251,000 after purchasing an additional 4,429 shares during the last quarter. 87.96% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
Several equities research analysts have weighed in on XYL shares. Stifel Nicolaus upped their target price on Xylem from $162.00 to $175.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. TD Cowen upped their target price on Xylem from $125.00 to $130.00 and gave the stock a "hold" rating in a research note on Tuesday, August 26th. Wall Street Zen upgraded Xylem from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays initiated coverage on Xylem in a research note on Friday, September 19th. They set an "overweight" rating and a $165.00 target price for the company. Finally, Cowen reiterated a "hold" rating on shares of Xylem in a report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $154.67.
Read Our Latest Report on Xylem
Insiders Place Their Bets
In related news, CAO Geri-Michelle Mcshane sold 1,000 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $139.96, for a total value of $139,960.00. Following the completion of the sale, the chief accounting officer directly owned 2,957 shares in the company, valued at $413,861.72. This represents a 25.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.27% of the stock is owned by insiders.
Xylem Stock Performance
NYSE XYL opened at $146.76 on Tuesday. The company has a market capitalization of $35.72 billion, a price-to-earnings ratio of 38.12, a PEG ratio of 2.49 and a beta of 1.13. Xylem Inc. has a twelve month low of $100.47 and a twelve month high of $151.16. The stock has a fifty day simple moving average of $143.39 and a 200 day simple moving average of $131.73. The company has a quick ratio of 1.43, a current ratio of 1.90 and a debt-to-equity ratio of 0.17.
Xylem (NYSE:XYL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The industrial products company reported $1.26 earnings per share for the quarter, beating analysts' consensus estimates of $1.15 by $0.11. The business had revenue of $2.30 billion during the quarter, compared to the consensus estimate of $2.20 billion. Xylem had a return on equity of 10.33% and a net margin of 10.74%.Xylem's quarterly revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the business posted $1.09 earnings per share. Xylem has set its FY 2025 guidance at 4.700-4.850 EPS. Sell-side analysts expect that Xylem Inc. will post 4.65 EPS for the current year.
Xylem Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 25th. Investors of record on Thursday, August 28th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Thursday, August 28th. Xylem's dividend payout ratio is presently 41.56%.
Xylem Profile
(
Free Report)
Xylem Inc, together with its subsidiaries, engages in the design, manufacture, and servicing of engineered products and solutions worldwide. It operates through four segments: Water Infrastructure, Applied Water, Measurement & Control Solutions, and Integrated Solutions and Services. The Water Infrastructure segment offers products, including water, storm water, and wastewater pumps; controls and systems; filtration, disinfection, and biological treatment equipment; and mobile dewatering equipment and rental services under the ADI, Flygt, Godwin, Sanitaire, Magneto, Neptune Benson, Ionpure, Leopold, Wedeco, and Xylem Vue brands.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xylem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xylem wasn't on the list.
While Xylem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.